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Monsanto and the Requirement for Real
Risks in GM Food Regulation
I. INTRODUCTION
Before beginning any discussion on the legal issues involving
genetically modified ("GM") foods, a brief explanation of the
science behind GM foods is in order. You may know from your
high school biology class that traits of living organisms are
inherited. For example, you may have inherited the color of your
eyes from your mother or your height from your father. "Genes"
are the key elements in this process of inheritance.! When genes
are modified, often the physical manifestations of these genes also
change.' Consequently, the aim of genetic modification is to
improve the productivity, quality, or performance of an organism.'
Genetic modification occurs from two sources - traditional
breeding techniques and genetic engineering.4 Traditional breeding
is based on crossing plants or animals to create a hybrid organism!
Genetic engineering, on the other hand, refers to the use of
scientific techniques (collectively known as "recombinant
technology"') that artificially move functional genes between
organisms or between species These inserted genes are called
"transgenes" and the products of these genes (such as proteins)
are called "transgenic" products.8 Consumer concern has mainly
1. THOMAS BERNAUER, GENES, TRADE, AND REGULATION: THE SEEDS OF
CONFLICT IN FOOD BIOTECHNOLOGY 24 (2003).
2. See id. at 23.
3. Id.
4. Michael W. Toffel & James E Heyman, An Atlantic Divide? European and
American Attitudes on Genetically Engineered Foods 3 (Haas Sch. of Bus., Univ. of
California, Working Paper, 2002), http://faculty.haas.berkeley.edu/toffellpapers/
AtlanticDivideManuscript.pdf (last visited Feb. 22, 2005).
5. Id. For example, a mule comes from breeding a donkey and a horse. A mule is a
hybrid.
6. AMGEN, RECOMBINANT DNA TECHNOLOGY, http://www.amgen.comlrnd/
RecombinantDNA.html (last visited Feb. 19, 2005).
7. Toffel & Heyman, supra note 4, at 3.
8. DEPT. OF SOIL & CROP SCIENCES AT COLORADO STATE UNIVERSITY,
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focused on transgenic foods. This note will refer to these foods
simply as "GM foods."
Genetic engineering has two distinct advantages over
traditional breeding, namely, the ability to control which genes will
be transferred, and the length of time it takes for the desired trait
to manifest Unlike traditional breeding, genetic engineering
allows for a more controlled transfer of one or a few specific genes
with known functions from one organism to another or even across
different species, such as from bacteria to corn." Genetic
engineering also allows for faster development of new food
products and increases the range of traits available for developing
new crop varieties." Therefore, genetic engineering allows growers
to produce more nutritional foods in larger quantities and in a
shorter period of time.'2
Accordingly, GM foods from this method have tremendous
potential to alleviate hunger throughout the world. As the world
population continues to increase while the available space for
farming continues to shrink, an increase in food production is
absolutely essential." GM foods will allow countries to meet this
rising demand. Despite this benefit, however, many people have
remained wary of consuming GM foods because of safety
concerns. A main health concern is that the transfer of genes from
one organism to another may result in the transfer of allergens,"
TRANSGENIC CROPS: AN INTRODUCTION AND RESOURCE GUIDE,
http://www.colostate.edu/programs/lifesciences/TransgenicCrops/what.html (last visited
Feb. 19,2005).
9. BERNAUER, supra note 1, at '23; James Stamps, Trade in Biotechnology Food
Products, 43 INT'L ECON. REV. 5 (2002), available at http://hotdocs.usitc.gov/docs/pubs/
internationaleconomicreview/PUB3571.PDF.
10. BERNAUER, supra note 1, at 23.
11. Stamps, supra note 9, at 5. Traditional breeding, on the other hand, can be time-
consuming because it may require breeding several generations to obtain a desired trait
and breed out unwanted characteristics. Id.
12. See Norman E. Borlaug, Ending World Hunger. The Promise of Biotechnology
and the Threat of Antiscience Zealotry, 124 PLANT PHYSIOLOGY 487, 487, 489 (1990). This
article also illustrates the many advances that genetic engineering has accomplished in the
field of agriculture, including increase in arable lands, amelioration of soil degradation
problems, reduction in overall herbicide and fertilizer use, and lower production costs.
13. U.N. Food and Agric. Org. [FAO], Comm. On Agric., 15th Sess., Biotechology:
Item 7 of the Provisional Agenda (1999), http://www.fao.org/unfaolbodies/COAGI
COAG15/x0074e.htm#P143_11723.
14. Marion Nestle, Allergies to Transgenic Foods - Questions of Policy, 334 NEW
ENG. J. MED. 726 (1996).
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rendering allergenic previously non-allergenic foods. The concern
is that people susceptible to certain allergens will eat foods that
they previously thought were safe for them to eat.
Consumer resistance to GM foods is fierce in Europe, and
this is reflected in the laws regulating them." These regulations, for
the most part, have eliminated trade in GM foods within the
European Union (EU). From 1998 to 2003, no GM products were
approved for sale within the EU.'6 Indeed, the EU did not lift the
5-year moratorium on GM foods until after the United States,
Canada, and Argentina commenced an action against it in the
World Trade Organization. The perceived safety risks associated
with GM foods have undermined their trade even as these
concerns remain unfounded. 8
The European Court of Justice's (ECJ) decision in the case of
Monsanto v. Presidenza del Consiglio dei Ministri"9 is significant
because it illustrates a more constructive approach to GMO
("genetically modified organism"'2 ) trade than those advocated by
people on opposite sides of the GMO debate. By holding that
novel foods containing transgenic proteins may still be considered
substantially equivalent to existing foods and emphasizing a risk
15. Elisabeth Rosenthal, Europe is United: No Bioengineered Food, INT'L HERALD
TRIBUNE, Oct. 6, 2004, available at http://www.iht.com/bin/print.php?file=542151.html
("Since the late 1990s the European Union has required that all food containing more
than tiny amounts of genetically modified materials be labeled, and that all genetically
modified products be submitted for approval before sale in Europe.").
16. Id.
17. Id. The current WTO dispute revolves around the issue of whether the EU's laws
and procedures that discriminate against GM products are unnecessary and thus constitute
an unfair barrier to trade. See Request for Consultations by the United States, European
Communities - Measures Affecting the Approval and Marketing of Biotech Products,
WT/DS291/1 (May 20, 2003), available at http://trade-
info.cec.eu.int/doclib/docs/2003/november/tradoc_114610.pdf; Request for Consultations
by Canada, European Communities - Measures Affecting the Approval and Marketing of
Biotech Products, WT/DS291/1 (May 20, 2003); Request for Consultations by Argentina,
European Communities - Measures Affecting the Approval and Marketing of Biotech
Products WTJDS293/1 (May 21, 2003). Subsequently, the EU adopted the GM Food and
Feed Law (Regulation 1829/2003) and GMO Traceability and Labeling Law (Regulation
1830/2003), which came into force on April 18, 2004 and finally made it possible to
transform and sell GM foods. Italy Not Opened to GMO Containing Foods, ANSA -
ENGLISH CORPORATE NEWS SERVICE, Nov. 9,2004, 2004 WL 98952238.
18. See BERNAUER, supra note 1, at 24-25.
19. Case C-236/01, Monsanto Agricoltura Italian SpA v. Presidenza del Consiglio dei
Ministri, 2003 E.C.R. 1-8105, available at http://curia.eu.int.
20. "Genetically modified organism" refers to either a genetically modified plant or
animal. Genetically modified foods come from GMOs.
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assessment based on real, perceived risks instead of hypothetical
risks,21 the Court strikes the proper balance between safety and
trade concerns. The Court's decision will likely have wide-ranging
implications on how novel foods will be regulated in the future. It
is also likely that the decision's effects will expand to include all of
GM foods, not just a subsection of it. With this decision, the Court
signaled to Member States that it is prepared to overturn, if
necessary, GM food regulations that are based on mere
hypothetical risks to health.
Although the issues presented here apply to all organisms or
products involving recombinant technology, this note will focus
solely on GM foods. Part II discusses the relevant provisions of
Directive 90/220 on the deliberate release of GMOs into the
environment and Regulation 258/97 concerning novel foods and
novel food ingredients ("Novel Foods Regulation"). Part III
recounts the facts of Monsanto. Part IV begins with a discussion of
the role of risk perception in foods and its effect on GM food
regulation. It then analyzes the Court's decision, keeping in mind
its impact on future GM food regulation, and how the Court's
emphasis on real, perceived risks strikes the proper balance
between safety and trade concerns.
II. LEGAL BACKGROUND
A. Council Directive 90/220/EEC
Council Directive 90/220/EEC ("Directive 90/220")' on the
deliberate release of GMOs into the environment forms "the
framework by which the member states of the EU approach their
cooperative system of food biotechnology regulation."23 Article
11(5) provides that a GM product may not be released into the
environment without the written consent of the competent
21. Monsanto, 2003 E.C.R. 1-8105 91 84.
22. Council Directive 90/220/EEC On the Deliberate Release into the Environment
of Genetically Modified Organisms, 1990 O.J. (L 117) 15, available at
http://europa.eu.int/smartapi/cgi/sga-doc?smartapi!celexapi!prod!CELEXnumdoc&lg=E
N&numdoc=31990L0220&model=guichett.
23. Jeffrey K. Francer, Frankenstein Foods or Flavor Savers?: Regulating Agricultural
Biotechnology in the United States and European Union, 7 VA. J. SOC. POL'Y & L. 257, 278
(2000).
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authority of the State where it is first released." It also provides for
a "case-by-case environmental risk assessment" prior to the
release of any GM product.' Directive 90/220 was amended in
2001 and renamed Directive 2001/18/EC,26 but the relevant
provisions pertaining to the case at hand remain unchanged.27
B. The Novel Foods Regulation
Regulation 258/97/EC, also known as the Novel Foods
Regulation, specifically deals with placing novel foods or novel
food ingredients on the market.28 Article 1(2) defines novel foods
or novel foods ingredients ("novel foods") as those containing or
consisting of GMOs as defined in Directive 90/220, or, those
produced from, but not containing, GMOs 9
The Novel Foods Regulation subjects novel foods to a safety,
or risk, assessment before they are placed on the market." One
way for novel foods to be placed on the market is through the
"simplified procedure."3' The simplified procedure requires a
company proposing to release novel foods into the Community
market to notify the Commission if its intent. 2 This notice is
accompanied by a written consent from a Member State's
competent authority, and a report regarding the food's
composition, nutritional value, metabolism, intended use, and level
of undesirable substances. The Commission then forwards a copy
of the notification to Member States within sixty days and if a
Member State so requests, a copy of the report." Additional
24. Council Directive 90/220, supra note 22, art. 11(5).
25. Id. pmbl.
26. Council Directive 2001/18, On the Deliberate Release into the Environment of
Genetically Modified Organisms and Repealing Council Directive 90/220/EEC, 2001 O.J.
(L 106) 1 (EC).
27. The requirement of article 11(5) of Directive 90/220 for a written consent from
the competent authority of the Member State can be found in article 13(1) of Directive
2001/18/EC. The requirement for a case-by-case assessment can be found in preamble (19)
of Directive 2001/18/EC.
28. Council Regulation 258/97, Concerning Novel Foods and Novel Food Ingredients,
preamble (2), 1997 O.J. (L 43) 1.
29. Id. art. 1(2).
30. Id. pmbl. (2).
31. Id. art. 5.
32. Id.
33. Id.
34. Id.
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specific labeling requirements ensure that the consumer is
informed of the novel foods' characteristics.35
To be marketed under the simplified procedure, novel foods
must be "substantially equivalent" to existing foods.36 According to
article 3(4), the novel foods are substantially equivalent to existing
foods if they are similar in composition, nutritional value,
metabolism, intended use, and the level of undesirable
substancesY.3  Recommendation 97/618/EC has broadened this
definition by stating that novel foods are substantially equivalent
to existing foods regardless of the difference in composition as
long as it has no effect on public health.8 If the novel foods are
substantially equivalent to existing foods, they may be inspected
using the same safety standards as existing foods - no more, no
less.39 Consequently, a comprehensive risk assessment is not
required.4" If the novel foods are not substantially equivalent to
existing foods, however, then the simplified procedure may not be
used to market the products, and a more comprehensive risk
assessment is required.
Under article 12, a Member State objecting to the
classification of the novel food as "substantially equivalent" to
existing foods has the power to enact measures temporarily
restricting or suspending the trade in and use of the novel food.
2
To do so, it must show the Commission and other Member States
that it has detailed grounds for considering the use of the novel
food as dangerous to human health or the environment.3
III. FACTS OF MONSANTO
In the present case, French and United Kingdom authorities
approved the marketing of certain novel foods within their
35. Id. art. 8.
36. Id. pmbl. (2).
37. Id. art. 3(4).
38. See Commission Recommendation 97/618, sec. 3.3, 1997 O.J. (L 253) 1, 6 (EC),
available at http://www.fsai.ie/legislation/food/eu-docs/NovelFoodsand-lngredients/
Recomm97.618.pdf (last visited Feb. 22, 2005).
39. Id.
40. Case C-236/01, Monsanto Agricoltura Italian SpA v. Presidenza del Consiglio dei
Ministri, 2003 E.C.R. 1-8105, 128, available at http://curia.eu.int.
41. Id. 129.
42. Council Regulation 258/97, supra note 28, art. 12.
43. Monsanto, 2003 E.C.R. 1-8105 11.
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respective territories." These foods were derived from genetically
modified maize with increased tolerance to herbicide and were
resistant to insects. 5 The finished food products no longer contain
GMOs, but did contain transgenic proteins.6 Monsanto and other
biotechnology companies subsequently notified the Commission
and other Member States of their intent to market the novel foods
throughout the Community. 7 The notifications were accompanied
by opinions from the competent UK authority stating that the
novel foods were "substantially equivalent to products derived
from conventional maize and were safe for use in food."'
The Italian Health Ministry lodged a complaint to the
Commission, objecting to the use of the simplified procedure and
stating that protective measures must be taken to ensure that the
novel foods were indeed safe and their potential health risks
rigorously assessed before they were placed on the market. 9 The
Commission replied that the condition of substantial equivalence
was satisfied and that the use of the simplified procedure was
therefore appropriate." In response, the Italian government
subsequently adopted the Decree of August 4, 2000 ("Decree"),
suspending the trade in and use of the novel foods." The Italian
government justified the Decree by stating that the absence of
detailed information and the referral to the Scientific Committee
for Food for the purpose of reassessing the effects of GMOs on
consumer health and on the environment constituted a sufficient
basis for the suspension of the marketing of the novel foods. 2
Monsanto, along with other biotechnology companies, filed
an action against the Italian government before the Italian
regional administrative court, called the Tribunale amministrativo
regionale del Lazio ("Tribunale"), seeking the repeal of the
Decree and full compensation for damages suffered while the
Decree was in effect.53 The Tribunale stayed the proceedings and
44. Id. 117.
45. Id.
46. Id. [ 21.
47. Id. IT 18, 20.
48. Id. [19.
49. Id. [ 24.
50. Id. 1 25.
51. Id. [ 16,31.
52. Id. 32.
53. Id. 140.
2006]
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submitted several questions regarding the proper interpretation of
the Novel Foods Regulation to the ECJ for a preliminary ruling."4
Prior to the Court's decision but after Monsanto submitted
the notifications under the simplified procedure to the
Commission, the Commission and Member States agreed to no
longer apply the simplified procedure to novel foods derived from
GMOs containing transgenic protein, effective beginning in 1998.",
Nevertheless, the Court held that the mere presence of transgenic
protein in novel foods did not preclude those foods from being
considered substantially equivalent to existing foods, and
consequently, from being marketed using the simplified procedure
at the time." If a Member State objects to the classification, it may
adopt measures preventing the marketing of novel foods within its
jurisdiction as long as the State, pursuant to Directive 90/220, first
carries out a safety assessment "which is as complete as possible
given the particular circumstances of the individual case." 7 In
addition, it must be apparent from the safety assessment that the
protective measures are necessary in order to ensure that the novel
foods are safe for consumption. In reaching this conclusion, the
Court reasoned:
If the twofold objective of [the Novel Foods Regulation],
namely ensuring the functioning of the internal market in novel
foods and protecting public health against the risks to which
those foods may give rise, is not to be adversely affected,
protective measures ... may not properly be based on a purely
hypothetical approach to risk, founded on mere suppositions
which are not yet scientifically verified. 9
IV. ANALYSIS
A. The Role of Risk Perception in Foods on GM Food Regulation
As this article will show, GM food regulation is heavily
influenced by how the public perceives risks in foods. In assessing
risk, the key issue is to determine whether a product's attendant
54. Id. [ 48.
55. Id. [ 21.
56. Id. 84.
57. Id. 114.
58. Id.
59. Id. I 106.
[Vol. 28:335342
Monsanto
risks are judged to be acceptable.' Among many European
consumers, the attendant risks of GM foods are simply
unacceptable.61 However, this was not always the case. In 1996,
Safeway and Sainsbury's, the United Kingdom's two largest
supermarket chains, began selling tomato puree made from
genetically engineered tomatoes." These modified tomatoes
required less heat and concentration before canning, thus costing
less to produce.63 The clearly-labeled product flew off the shelves;
by late 1997 Safeway's stores had sold 750,000 cans.' By July 1999,
however, both Safeway and Sainsbury's had withdrawn the
product, mainly because of pressure from consumer groups.
5
Public opposition against genetically engineered food became so
fierce, not just in the UK but throughout Europe, that some
politicians won elections by vowing to keep "Frankenfoods" at
bay.'
Several factors contribute to the perception that the risks
presented by GM foods are simply unacceptable. First, food is
"high culture, if not religion" in Europe.67 Europeans tend to be
more attached to national culinary traditions and are more likely
to expect food products to be fresh and natural compared to their
American counterparts.6' Thus, they view foods produced through
60. E.I.L. VOS, OVERCOMING THE CRISIS OF CONFIDENCE: RISK REGULATION IN
AN ENLARGED EUROPEAN UNION 8, at http://www.unimaas.nl/bestand.asp?id=2066
(January 23, 2004).
61. See Rosenthal, supra note 15.
62. BERNAUER, supra note 1, at 24:
63. Id.
64. Id.
65. Id.
66. Lizette Alvarez, Consumers in Europe Resist Gene-Altered Foods, N.Y. TIMES 3,
Feb. 11, 2003 (describing how some politicians in Austria won their seats by opposing GM
foods). A recent survey in Italy showed that only 13% of Italians were willing buy
foodstuffs containing GMOs and only at discount prices. Italy Not Opened to GMO
Containing Foods, supra note 17.
67. Rosenthal, supra note 15. One author, reflecting the views of pro-trade groups,
suggests that the strong anti-GM stance in Europe is based on more than just "cultural
preferences" and mistrust of food safety regulators but is instead simply based on classical
trade economics. Lawrence A. Kogan, Ducking the Truth about Europe's GMO Policy
Trade Protectionism, INT'L HERALD TRIBUNE, Nov. 27, 2004, available at
http://www.iht.com/bin/print -ipub.php?file=/artices/2004/11/26/opinion/edkogan.html. See
Lawrence A. Kogan, Exporting Europe's Protectionism, THE NATIONAL INTEREST, Oct.
1, 2004, 2004 WL 76694309, for an in-depth critique of EU's stringent GM regulations.
68. Paulette Kurzer, European Citizens against Globalization: Public Health and Risk
Perceptions 20, (Martindale Ctr., Coll. Of Bus. & Econ., Lehigh Univ., Working Paper,
2006]
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genetic engineering with deep suspicion. Second, there is a general
mistrust of EU regulatory and public health agencies, most likely
because of their perceived failure in preventing a string of food
scandals, most notably the outbreak of bovine spongiform
encephalopathy ("BSE", or mad-cow disease) and its human
equivalent Creutzfeldt-Jacob disease ("CJD") in 1996.0 EU and
Member State authorities at that time reassured anxious
consumers that BSE was not transmissible from ruminants to
humans, a claim that ended up being both unwarranted and
untrue." This incident, and others, such as the 1999 contamination
of Coca-Cola products in Belgium and France,7 shook the public's
trust in the judgment of government officials and experts in the
field of consumer protection. 2 Third, the horrific manner of death
resulting from CJD heightened public concern over what they
were eating.73 Although concern over GM foods were present prior
to the outbreak of BSE, the outbreak created a backlash against
GM foods, and whatever inroads they have made in the European
market by 1996 quickly disappeared. The combination of these
factors contributed to the consumer perception that the risk to
public health will greatly increase if GM foods were freely released
in the market.
The EU's broad legislative framework regulating GM foods
reflects the public's concerns regarding them. Indeed, the BSE
crisis forced the European Community to take firm action to
reform the European food safety system." In the aftermath of the
BSE crisis, the EU adopted the Treaty of Amsterdam, which
2004), available at http://www.lehigh.edu/martindale/publications/kurzer.pdf. See also
Toby A. Ten Eyck, George Gaskell & Jonathan Jackson, Seeds, food and trade wars:
Public opinion and policy responses in the USA and Europe, 10 JOURNAL OF
COMMERCIAL BIOTECHNOLOGY 258, 258 (2004) ("In the minds of at least some
countries, food is in a different category from other traded products. It is part of national
and regional identity; the imposition of novel foods that challenge deeply held cultural
values is likely to be resisted.").
69. Stamps, supra note 9, at 9.
70. Kurzer, supra note 68, at 17.
71. Stamps, supra note 9, at 9.
72. Kurzer, supra note 68, at 17.
73. Aynsley Kellow, Risk Assessment and Decision-making for Genetically Modified
Foods, 13 RISK 115,134 (2002).
74. Karolina Szawlowska, Risk Assessment in the European Food Safety Regulation:
Who is to Decide Whose Science is Better? Commission v. France and Beyond, 5 GERMAN
L.J. 1259, 1262-63 (2004).
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required that all Community policies and action ensure a high
level of protection to human health and environment.75 There is a
concern, however, that too much regulation will stifle the free
movement of goods within the EU, which is guaranteed by the
Treaty Establishing the European Community ("EC Treaty").76
Too much regulation also has the effect of stifling scientific
progress in food biotechnology in the EU, considering that no
studies have shown that consuming GM foods is detrimental to
one's health."' On the other hand, the EC Treaty and the Treaty of
Amsterdam do guarantee the protection of human health and the
environment.79 The Monsanto case perfectly illustrates the tension
between the free movement of goods, GM foods in particular, and
the protection of human health.
B. Risk Assessment Based on Real Risks
The Court's emphasis on a risk assessment based on real and
perceived risks instead of hypothetical risks is an eminently
sensible approach to novel foods and could lead to a shift in the
way the Member States approach GM food regulation. Instead of
relying on mere suppositions that are not yet scientifically
verified,' the Court held that a Member State must have detailed
grounds for considering the use of novel foods as endangering
human health. 1 This requirement ensures that Member States do
75. Id.; Treaty of Amsterdam Amending the Treaty on European Union, the Treaties
Establishing the European Communities and Certain Related Acts, Oct. 2, 1997, O.J. (C
340) 1 [hereinafter Treaty of Amsterdam].
76. Treaty Establishing the European Community, Nov. 10, 1997, 1997 O.J. (C 340) 3,
arts. 3(1)(c), 14(2) [hereinafter EC Treaty].
77. According to the European Commission, "[t]he lack of progress on the
authorizations of new GMOs is having a direct impact on research activities on GMOS
and GMO field trials in Europe." Life Sciences and Biotechnology - A Strategy for
Europe: Progress Report and Future Orientations, Communication from the Commission
to the European Parliament, to the Council and to the European Economic and Social
Committee, COM(03)96 final at 17, http://europa.eu.int/comm/
biotechnology/pdf/com2003-96-en.pdf (last visited Jan. 15, 2005). A survey of
biotechnology companies and research institutes showed that 39% have cancelled research
and development projects on GMOs over the last four years, blaming the unclear
regulatory framework and uncertain market situation. Id. at 18.
78. See BERNAUER, supra note 1, at 24-25.
79. EC Treaty, supra note 76, art. 174(1).
80. Case C-236/01, Monsanto Agricoltura Italian SpA v. Presidenza del Consiglio dei
Ministri, 2003 E.C.R. 1-8105, 106, available at http://curia.eu.int.
81. Id. 108.
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not misuse their regulatory powers' by impeding the trade in novel
foods without adequate proof that the foods endanger human
health. In addition, the holding opens the door for a similar
framework if broadened to apply not just to novel foods, but also
to GM foods in general. This approach will go a long way towards
other nations' acceptance of GM foods, especially nations sorely in
need of GM foods to meet their populations' food and nutritional
requirements.
1. Substantial Equivalence
The Court's decision may seem to be less protective of human
health given the uncertainty of the effects of transgenic proteins
present in novel food. In the case at hand, Italy believed that the
use of substantial equivalence was not sufficient to ensure a high
level of protection to human health and environment. 3 Substantial
equivalence, however, is not the beginning and the end of a safety
assessment, but a precondition to determine whether the novel
food will be marketed under a simplified procedure.u According to
the Court, if the analysis for substantial equivalence identifies
hazards, then the food in question is subject to a full scientific risk
assessment.' As the Court pointed out, substantial equivalence is
but one approach to comparing the novel food with its
conventional counterpart in determining whether it should be
subject to a risk assessment.'
2. The Simplified Procedure Does Not Change the Risk
Assessment Process
The Court also pointed out that the simplified procedure
should not be considered as relaxing the safety requirements with
82. Member States may adopt measures restricting the free movement of goods in
their respective territories to protect public health, but these prohibitions must neither be
arbitrary nor merely a disguised restriction on trade between Member States. Julien
Cazala, Food Safety and the Precautionary Principle: the Legitimate Moderation of
Community Courts, 10 EUR. L. J. 539, 550 (2004); EC Treaty, supra note 76, art. 30 (ex art.
36).
83. See Monsanto, 2003 E.C.R. 1-8105 $ 23-24.
84. Patrycja Dabrowska, GM Foods, Risk, Precaution and the Internal Market: Did
Both Sides Win the Day in the Recent Judgment of the European Court of Justice?, 5
GERMAN L.J. 151, 156 (2004).
85. Monsanto, 2003 E.C.R. 1-8105 79.
86. Id. 77.
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respect to novel foods.87 Other steps are involved to ensure a high
level of protection to public health. For example, the status of a
GMO-derived product may be re-assessed by the Commission.'
Additionally, labeling requirements inform consumers of the GM
content of a product.89 Finally, article 12 of the Novel Foods
Regulation explicitly provides that a Member State may take
protective measures, if it has "detailed grounds" for considering
that the novel foods endanger human health or the environment.
In the present case, Italy's reasons for adopting the Decree - the
mere observations of its competent authority of the presence of
transgenic proteins' - quite obviously lacked the specificity that
the Novel Foods Regulation requires.
Although the Member States and the Commission agreed to
no longer use the simplified procedure, it does not lessen the
impact of the decision on the regulation of novel foods and how it
will affect GM food regulation in general. Even in the absence of a
simplified procedure, there still must be detailed grounds before
any Member State adopts protective measures." That is, the
absence of a simplified procedure does not change the
requirement for a risk assessment based on real, perceived risks in
regulating novel foods.
3. Court's Decision is Consistent with the Precautionary Principle
The Court's approach is also perfectly consistent with the
precautionary principle, which EU GM food regulations strongly
emphasize.' The principle allows the adoption of measures to
prevent health and environmental harms even if scientific
uncertainty still exists.93 To supporters of stricter food safety
regulation, this means "when in doubt, refrain."" That is, the
87. Id. 80.
88. Dabrowska, supra note 84, at 158.
89. See Council Regulation 1830/2003, 2003 O.J. (L 268) 24.
90. Monsanto, 2003 E.C.R. 1-8105 55.
91. According to the Court, "The applicability of Article 12 is not affected by the type
of procedure which was followed prior to the placing on the market of the novel foods -
namely the simplified procedure or the normal procedure - or, in principle, by the validity
of the procedure which was followed." Id. T[ 104.
92. BERNAUER, supra note 1, at 45. E.C. Treaty art. 174 explicitly provides that
measures to protect the environment should be based on the precautionary principle.
93. DAVID HUNTER ET AL., INTERNATIONAL ENVIRONMENTAL LAW AND POLICY
406 (2d ed. 2002).
94. Cazala, supra note 82, at 542.
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principle obliges competent authorities to ban an activity or
product "from the moment when the scientific community raises
the specter of possible risks for human health or the
environment. '" 9' The Court takes a more level-headed approach,
applying the principle only where preliminary risk assessment
indicates that there are "reasonable grounds for concern" of
potentially dangerous effects on the environment, human, animal
or plant health.96 Under the precautionary principle espoused by
those who favor stricter regulations, the idea of some vague risk
that may come with consuming GM foods in the distant future
would allow for the ban of these products. Under the Court's
interpretation of the precautionary principle, however, more than
mere supposition is needed.
The Italian government's decision to adopt the Decree is
clearly based on mere suppositions of risk. Italy's real objection
about the products is not about the risks they might pose, but
about the use of the simplified procedure and -substantial
equivalence.97 Italy temporarily banned the novel foods months
before the Italian Health Institute first noted the presence of
transgenic protein in the foods.98 Indeed, the Institute noted its
presence just weeks before the Decree was enacted." In addition,
the risk assessment reports the government relied on stated that
the consumption of the novel foods at issue does not present any
danger to human and animal health.'" The Italian government's
argument, therefore, was not that the foods were unsafe, but that
there should have been another layer of analysis before permitting
the foods into the market, regardless of how substantially
equivalent they were to conventional foods.'"' This approach
clearly cannot be considered reasonable in light of the EC Treaty's
95. Id.
96. HUNTER, supra note 93, at 407.
97. THUS E'rY & HAN SOMSEN, CASE C-236/01 - MONSANTO, at
http://www.jur.uva.nl/cvm/object.cfm/objectlD=BC8AFBBD-89D7-4A16-
832E5C96D3E63AD1 (last visited Jan. 13, 2005).
98. Id.
99. Id.
100. Case C-236/01, Monsanto Agricoltura Italian SpA v. Presidenza del Consiglio dei
Ministri, 2003 E.C.R. 1-8105, $ 30, available at http://curia.eu.int.
101. See Opinion of Advocate General Alber, Monsanto Agricoltura Italian SpA v.
Presidenza del Consiglio dei Ministri, Case C-236/01, 2003 E.C.R. 1-8105, 46 [hereinafter
A.G. Opinion], available at http://curia.eu.int.
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purpose of promoting the free movement of goods.'"
4. Court's Decision Strikes the Proper Balance between Public
Health and Trade Concerns
The problem with the Italian Decree is that it unnecessarily
impedes trade in GM foods. Giving Member States unfettered
authority to adopt measures based on mere hypothetical risks to
health would only lead to confusion among consumers and
business groups. It would also only serve to undermine the
purpose of a common market, which is to promote the free
movement of goods within the EU. In addition, Italy and the EU
have certain obligations under the WTO to ensure the free
movement of goods, with certain exceptions. 3 Even these
exceptions, however, require more certainty that mere
suppositions."
The Court's decision also has the effect of encouraging other
nations to look upon GM foods with less suspicion. The EU's
position as one of the largest markets in the world gives it
considerable sway on what kind of items other nations view as
tradable commodities. The EU's unfavorable position regarding
GM foods led other nations to refuse to grow them because doing
so would have limited their agricultural exports to the EU
market.'°5 The Court's decision requiring real risks instead of
hypothetical risks, in addition to recently enacted law,1" should
encourage other nations, especially poor nations, to grow GM
foods and allow them the opportunity to meet the food and health
102. See EC Treaty, tit. I.
103. The General Agreement on Tariffs and Trade ("GATT"), which States must
accept in order to become part of the WTO, requires, among other things, the removal of
restrictions that would limit the quantity of imports permitted. HUNTER, supra note 93, at
1147.
104. Article XX of GATT provides a health exception to GATT obligations, allowing
Member States to adopt measures "necessary" to protect human life or health. Id. at 1163.
In addition, art. 2.2 of the Agreement on the Application of Sanitary and Phytosanitary
Measures ("SPS Agreement") requires Member States to "ensure that any sanitary and
phytosanitary measure is applied only to the extent necessary to protect human, animal or
plant life or health." Id. at 1165. GATT panels have consistently favored a narrow
interpretation of "necessary." Id.
105. For example, Zambia, Zimbabwe, Mozambique, and Malawi sought to prevent
imported GM food products from contaminating their domestic crops and jeopardizing
exports to the EU. Stamps, supra note 9, at 14. See also Rosenthal, supra note 15.
106. See Rosenthal, supra note 15.
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requirements of their growing populations.
V. CONCLUSION
The Court, in holding that mere presence of transgenic
proteins in novel foods does not necessarily preclude them from
being considered substantially equivalent to existing foods, strikes
the proper balance between public health concerns and trade
concerns. The Court was careful to emphasize that the decision
does not amount to a relaxation of the safety requirements that
must be met by novel foods. 7 Public health is safeguarded by risk
assessment, re-assessment of the novel foods by Member States
and at the Community level, and labeling requirements.'" Trade
will be permitted only if the risk assessment does not yield
reasonable grounds for concern."° This decision, with the emphasis
on risk assessment based on real, perceived risks, opens the door
for a more balanced approach on regulation not just of novel
foods, but also of GM foods in general. Considering their
enormous potential, European laws that focus on real, perceived
risks of GM foods will go a long way towards removing the stigma
currently associated with GM foods and perhaps finally begin to
fulfill its potential of alleviating hunger all over the world.
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